Anti‐<scp>TNF</scp>‐α therapy improves insulin sensitivity in non‐diabetic patients with psoriasis: a 6‐month prospective study

Pina, Trinitario; Armesto, Susana; López‐Mejías, Raquel; Genre, Fernanda; Ubilla, Begoña; González‐López, Marcos A.; González‐Vela, M. Carmen; Corrales, Alfonso; Blanco, Ricardo; García-Unzueta, Mayte; Hernández, José L.; Llorca, Javier; González-Gay, Miguel Á.

doi:10.1111/jdv.12814

Cited by 58 publications

(68 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table summarizes the epidemiological and clinical features of these 29 patients immediately prior to the onset of adalimumab therapy. As previously reported, at 6 months after the onset of adalimumab a significant reduction ( P < 0.05 for each comparison) in all of the markers of disease activity and severity including ESR, usCRP, BSA, PASI, NAPSI, PGA and PASE was observed . In this regard, BSA and PASI experienced a significant reduction (BAS from 37.9 ± 16.3% to 3.1 ± 5.5; PASI from 18.9 ± 7.8 to 1.3 ± 2.1).…”

Section: Resultssupporting

confidence: 77%

See 1 more Smart Citation

Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate‐to‐severe psoriasis undergoing anti‐tumor necrosis factor‐α therapy

Pina

Genre

López‐Mejías

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

Patients with psoriasis, in particular those with severe disease, have an increased risk of cardiovascular (CV) events compared with the general population. The aim of the present study is to determine whether correlation between asymmetric dimethylarginine (ADMA) and osteoprotegerin (OPG), two biomarkers associated with CV disease, and disease severity may exist in patients with moderate-to-severe psoriasis. We also aimed to establish if baseline serum levels of these two biomarkers could correlate with the degree of change in the clinical parameters of disease severity following the use of anti-tumor necrosis factor (TNF)-α therapy in these patients. This was a prospective study on a series of consecutive non-diabetic patients with moderate-to-severe psoriasis who completed 6 months of therapy with anti-TNF-α-adalimumab. Patients with kidney disease, hypertension or body mass index of 35 kg/m(2) or more were excluded. Metabolic and clinical evaluation was performed immediately prior to the onset of treatment and at month 6. Twenty-nine patients were assessed. Unlike OPG, a significant positive correlation between ADMA and resistin serum levels was found at the onset of adalimumab and also after 6 months of biologic therapy. We also observed a positive correlation between the percent of body surface area affected (BSA) and ADMA levels obtained before the onset of adalimumab and a negative correlation between baseline ADMA levels and a 6-month BSA change compared with baseline results. In patients with moderate-to-severe psoriasis, ADMA levels correlate with clinical markers of disease severity.

show abstract

Section: Resultssupporting

confidence: 77%

“…Arthralgia was often described by the patients but none of them had a clinical pattern of psoriatic arthritis. The recruitment protocol has been previously described . Briefly, psoriatic patients with diabetes, kidney disease, hypertension or body mass index of 35 kg/m 2 or more were excluded.…”

Section: Methodsmentioning

confidence: 99%

Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate‐to‐severe psoriasis undergoing anti‐tumor necrosis factor‐α therapy

Pina

Genre

López‐Mejías

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The hypothesis that anti‐TNF‐α therapy can have a beneficial effect in the risk of atherosclerosis is getting stronger. In a cohort of 29 patients treated for 6 months with adalimumab therapy, a statistically significant improvement ( P = 0.008) of insulin sensitivity was observed after adalimumab treatment . The same authors showed that anti‐TNF‐α therapy achieved statistically significant reduction ( P = 0.0001) of retinol‐binding protein 4 (RBP4) serum levels.…”

Section: Discussionmentioning

confidence: 93%

Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study

Gkalpakiotis

Arenberger

Gkalpakioti

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-a, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: Creactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/b-glycoprotein I complex (oxLDL/b2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-b2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-a seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.

show abstract

“…We consecutively enrolled patients with moderate‐to‐severe psoriasis over an 18‐month period from the Dermatology outpatient clinics of the University Hospital Marques de Valdecilla (Santander, Northern Spain). Recruitment protocol has been previously described . Psoriatic patients with diabetes, kidney disease, hypertension or body mass index ≥ 35 kg/m 2 were excluded.…”

Section: Methodsmentioning

confidence: 99%

“…Previously, in a prospective study of psoriatic patients with active disease, we disclosed a beneficial effect of adalimumab, a fully human monoclonal antibody targeted against TNF‐α, on the mechanism associated with accelerated atherogenesis, specifically on insulin resistance …”

Section: Introductionmentioning

confidence: 99%

Anti‐TNF‐α therapy reduces retinol‐binding protein 4 serum levels in non‐diabetic patients with psoriasis: a 6‐month prospective study

Pina

Genre

López‐Mejías

et al. 2015

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

Anti‐TNF‐α therapy improves insulin sensitivity in non‐diabetic patients with psoriasis: a 6‐month prospective study

Abstract: Our results support a beneficial effect of the anti-TNF-α blockade on the mechanisms associated with accelerated atherogenesis in patients with psoriasis.

Cited by 58 publications

References 54 publications

Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate‐to‐severe psoriasis undergoing anti‐tumor necrosis factor‐α therapy

Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate‐to‐severe psoriasis undergoing anti‐tumor necrosis factor‐α therapy

Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study

Anti‐TNF‐α therapy reduces retinol‐binding protein 4 serum levels in non‐diabetic patients with psoriasis: a 6‐month prospective study

Contact Info

Product

Resources

About